Study of Pomegranate Juice on Memory in Older Adults

NCT02093130 | Completed Phase 2

• 1 other identifier: 13-001644
• Study Type: interventional
• Target: 212
• Locations: 1 country
• Sites: 1

Brief Summary

This project is designed to study whether pomegranate juice benefits cognitive abilities in middle-aged and older non-demented volunteers. Subjects will be randomly assigned to one of two treatment groups: either a placebo or the pomegranate juice. Subjects will drink eight ounces of the pomegranate juice or placebo daily for twelve months. The investigators expect the people receiving the pomegranate juice to show better cognitive performance compared with those receiving a placebo after one, six, and twelve months. The investigators believe cognitive decline and treatment response will vary according to a genetic risk for Alzheimer's. The investigators will study 212 non-demented subjects aged 50-75 years. Initially, subjects will undergo a clinical assessment, an MRI and a blood draw to determine genetic risk and to rule out other neurodegenerative disorders linked to memory complaints. Subsequently, subjects will undergo the first memory (or neuropsychological) assessments. Following the first assessment, subjects will begin drinking the juice (either the pomegranate juice or the placebo). Subjects will undergo a brief memory test at one-month mark. At six months, subjects will have a second, full neuropsychological assessment. The final assessment will take place at the end of the study, the 12-month mark. Additional blood will be drawn at baseline and at 12 months and frozen to assess inflammatory markers if outcomes are positive. In total, subjects will be expected to come to the University of California, Los Angeles (UCLA) for 5 visits during the course of 12-13 months.

Conditions

Impact of Pomegranate Juice on Memory in Older Adults

Keywords

Double-blind Trial; Placebo-controlled; Pomegranate; Memory; Memory Impairment; Cognition; Ages 50-75

Outcome Measures

Primary Outcomes (1)

• Change in cognitive testing results from Baseline to 1, 6, and 12 months

  Non-demented volunteers aged 50-75 who receive a daily dietary supplement of pomegranate juice will show improved cognitive performance compared to baseline versus those receiving a placebo after one, six, and twelve months.

  1 year

Secondary Outcomes (1)

• Correlation between cognitive change and genotype

  1 year

Study Arms (2)

Pomegranate Juice

EXPERIMENTAL

Eight ounces of 100% Pomegranate Juice daily

Dietary Supplement: Pomegranate Juice

Placebo

PLACEBO COMPARATOR

Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.

Dietary Supplement: Placebo

Interventions

Pomegranate Juice DIETARY_SUPPLEMENT

Pomegranate Juice

Placebo DIETARY_SUPPLEMENT

Placebo

Eligibility Criteria

• Age: 50 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Agreement to participate in the 12-month double-blind, placebo-controlled clinical trial of pomegranate extract.
• Nondemented subjects either those with normal cognition or with Mild Cognitive Impairment will be included.
• Age 50 to 75 years.
• No significant cerebrovascular disease: modified Ischemic Score of \< 4
• Adequate visual and auditory acuity to allow neuropsychological testing.
• Screening laboratory tests and EKG without significant abnormalities that might interfere with the study. If screening laboratory tests or EKG show abnormalities, subject must obtain written clearance from primary care physician before continuing in the study.

You may not qualify if:

• Diagnosis of probable Alzheimer's disease (AD) or any other dementia (e.g., vascular, Lewy body, frontotemporal) (McKhann et al, 1984). Evidence of other neurological or physical illness that can produce cognitive deterioration. Volunteers with a history of stroke, Transient Ischemic Attack (TIA), carotid bruits, or lacunes on MRI scans will be excluded. Determination of dementia will be based on the clinical evaluation including assessment of functional abilities, and cognitive screening.
• Contraindication to the MRI including claustrophobia, metal in body, surgery within 60 days, certain implants or previous abnormal MRI results.
• Evidence of Parkinson's disease as determined by the motor examination (items 18-31) of the Unified Parkinson's Disease Rating Scale (Fahn et al, 1987).
• History of myocardial infarction within the previous year, or unstable cardiac disease.
• Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100).
• History of significant liver disease, clinically-significant pulmonary disease, or diabetes.
• Current diagnosis of any major psychiatric disorder.
• Current diagnosis or history of alcoholism or substance addiction.
• Regular use of any medication that may affect cognitive functioning including: centrally active beta-blockers, narcotics, Clonidine, anti-Parkinsonian medications, antipsychotics, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or Warfarin.
• Occasional use of anxiety or sleeping medications known to cause cognitive dulling will be allowed, but discouraged: chloral hydrate, non-benzodiazepine hypnotics such as: Ambien (Zolpidem) and Lunesta; or benzodiazepines such as Ativan (Lorazepam), Xanax (Alprazolam), Klonopin (Clonazepam), and Restoril (Temazepam).
• Use of any of the following medications: Amitriptyline, Amiodarone, Desipramine, Fenofibrate, Flecainide, Fluconazole, Fluoxetine, Fluvastatin, Fluvoxamine, Isoniazid, Lovastatin, Ondansetron, Phenylbutazone, Probenecid, Sertraline, Sulfamethoxazole, Sulfaphenazole, Teniposide, Voriconazole, Warfarin, and Zafirlukast
• Use of cognitive enhancing supplements (e.g. Ginkgo biloba).
• Use of any supplement containing pomegranate or pomegranate juice.
• Use of any investigational drugs within the previous month or longer, depending on drug half-life.
• Pregnancy.

Sponsors & Collaborators

• University of California, Los Angeles: lead
• POM Wonderful LLC: collaborator

Study Sites (1)

UCLA Longevity Center

Los Angeles, California, 90095, United States

Location

Related Publications (2)

• Siddarth P, Thana-Udom K, Ojha R, Merrill D, Dzierzewski JM, Miller K, Small GW, Ercoli L. Sleep quality, neurocognitive performance, and memory self-appraisal in middle-aged and older adults with memory complaints. Int Psychogeriatr. 2021 Jul;33(7):703-713. doi: 10.1017/S1041610220003324. Epub 2020 Sep 28.

  PMID: 32985406 DERIVED

• Siddarth P, Li Z, Miller KJ, Ercoli LM, Merril DA, Henning SM, Heber D, Small GW. Randomized placebo-controlled study of the memory effects of pomegranate juice in middle-aged and older adults. Am J Clin Nutr. 2020 Jan 1;111(1):170-177. doi: 10.1093/ajcn/nqz241.

  PMID: 31711104 DERIVED

Related Links

• UCLA Longevity Center

MeSH Terms

Conditions

Memory Disorders

Condition Hierarchy (Ancestors)

Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Gary Small, MD

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Psychiatry and Biobehavioral Sciences

Study Record Dates

• First Submitted: March 14, 2014
• First Posted: March 20, 2014
• Study Start: January 1, 2014
• Primary Completion: May 1, 2018
• Study Completion: May 1, 2018
• Last Updated: March 2, 2020

Record last verified: 2020-02

Locations

US (1)